Parker Bioscience Expands Manufacturing of Single-Use Components

News
Article

Parker Bioscience Filtration added a cleanroom at its site in Birtley, UK for manufacturing single-use assemblies and sensors used in biopharmaceutical processing.

Parker Bioscience Filtration has expanded its manufacturing capabilities with the launch ofa new ISO class 7 cleanroom facility at its site in Birtley, United Kingdom. The cleanroom, which opened this month, forms part of a major phased investment program at the Birtley site and will be dedicated to the manufacture of single-use assemblies used in biopharmaceutical manufacturing. The assemblies are supplied to customers fully assembled and pre-irradiated, ready for direct use in their cleanroom facilities in the manufacture of drug products.

In tandem with the launch of the new cleanroom, the Birtley site will add a new manufacturing area for single-use sensing technologies used in biopharmaceutical manufacturing. These allow users to monitor key process parameters such as temperature, pressure, and conductivity.

The new 600-mcleanroom adds capacity for single-use technologies at the UK site, which already has 2400 mof cleanroom facilities dedicated to the manufacture of filtration products and the manufacture of single-use assemblies. The new cleanroom strengthens the company’s ability to serve biopharmaceutical manufacturers in the European market and complements existing single-use assembly manufacturing operations in the United States. The company plans to also expand laboratory, office, and warehouse facilities at the Birtley site.

Parker Bioscience Filtration, which is part of Parker Hannifin, designs, supplies, and delivers whole systems for both upstream and downstream pharmaceutical and biopharmaceutical manufacturing. The company combines filtration, single-use fluid-handling systems, and sensors into automated single-use solutions.

Source: Parker Hannifin 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content